The New Era of Alzheimer’s Diagnosis: How Blood Tests are Changing the Game
For decades, diagnosing Alzheimer’s disease has been a complex and often invasive process. Patients typically faced a choice between painful cerebrospinal fluid draws or expensive, high-tech PET scans—neither of which are available in a standard primary care setting. However, a major shift is underway. The emergence of highly accurate blood tests is moving Alzheimer’s detection out of specialty clinics and into the doctor’s office, offering a faster and more accessible path to diagnosis.
The FDA Breakthrough: Lumipulse
A pivotal moment occurred in May 2025, when the FDA approved the first blood test for the early detection of Alzheimer’s disease, called Lumipulse. This test is specifically intended for individuals aged 55 or older who are exhibiting signs or symptoms of the disease.
While other blood tests have been available for clinical use or marketed directly to consumers, Lumipulse is the first to navigate the rigorous FDA regulatory process. This approval is a game-changer given that it paves the way for standardized safety regulations and, crucially, coverage by public and private insurance. Previously, patients seeking similar biomarker tests often had to pay out-of-pocket, with costs ranging from $300 to $1,750.
How Blood Tests Detect Alzheimer’s
These tests don’t look for the disease itself, but rather for biological markers—proteins that signal the disease’s presence in the brain. Specifically, they measure proteins called amyloid beta and tau.
In a healthy brain, these proteins are managed efficiently. However, in Alzheimer’s patients, abnormal buildups of amyloid beta and tau occur. When these levels grow excessive, the proteins “spill” from the brain into the bloodstream, where they can be detected via a simple blood draw. Among these markers, phosphorylated tau 217 (p-tau217) has emerged as one of the most reliable and accurate biomarkers available.
Accuracy: Blood Tests vs. Clinical Evaluation
The precision of these tests far exceeds traditional clinical evaluations. Research funded in part by the NIH, led by experts at Lund University, tested a biomarker tool called PrecivityAD2. This test measures the ratio of two amyloid beta types and the proportion of p-tau217.
The results highlight a significant gap in diagnostic accuracy:
- Blood-Based Testing: Identified Alzheimer’s correctly in older adults with approximately 90% accuracy.
- Specialty Memory Clinics: Clinical evaluations without biomarkers were 73% accurate.
- Primary Care Settings: Clinical evaluations without biomarkers dropped to 61% accuracy.
Why This Matters for Patients
The ability to diagnose Alzheimer’s in a primary care clinic removes critical bottlenecks in patient care. Most people with cognitive complaints first visit their primary doctor. When the diagnosis requires a PET scan or spinal tap, the process slows down, often preventing patients from receiving drugs that can slow the progression of the disease. By simplifying the process, more people can access timely treatments and participate in clinical studies for new therapies.
Key Takeaways
- FDA Approved: Lumipulse became the first FDA-approved blood test for early Alzheimer’s detection in May 2025.
- Target Audience: The approved test is for those 55+ showing symptoms of the disease.
- High Precision: Some blood tests, like PrecivityAD2, show roughly 90% accuracy, far surpassing standard clinical exams.
- Biomarkers: Tests focus on amyloid beta and p-tau217 proteins that leak from the brain into the blood.
- Better Access: Blood tests allow primary care physicians to diagnose the disease without needing expensive imaging or invasive procedures.
Frequently Asked Questions
Who should get an Alzheimer’s blood test?
According to FDA guidelines for the Lumipulse test, it is intended for people ages 55 or older who are already showing signs or symptoms of the disease.
Are these tests a complete replacement for PET scans?
Blood tests are now considered reliable alternatives to brain imaging and invasive spinal fluid tests, providing a simpler and more cost-effective way to reach a diagnosis.
Will insurance cover these tests?
FDA approval is a critical step toward insurance coverage. While previous non-approved tests were often out-of-pocket expenses, the regulatory approval of tests like Lumipulse is expected to make them part of the standard of care.
Looking Ahead
The transition to blood-based diagnostics marks a new chapter in neurology. By reducing the cost and invasiveness of testing, the medical community can identify Alzheimer’s earlier and more accurately. This shift not only empowers patients with answers but too ensures that life-altering treatments reach those who need them most, far sooner than was previously possible.